NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.58 USD
-0.01 (-1.52%)
Updated Aug 7, 2025 03:57 PM ET
After-Market: $0.58 0.00 (-0.31%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBY 0.58 -0.01(-1.52%)
Will NBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBY
Brookdale Senior Living (BKD) Reports Q1 Loss, Lags Revenue Estimates
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
NBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
Other News for NBY
Catalyst Watch: Monster earnings week includes Microsoft, Apple, Amazon, and Mastercard
NioBay Metals Elects Board and Grants Stock Options at AGM
NioBay Metals Launches 2025 Drilling Campaign on Crevier Project
NioBay Metals Initiates First Product Deliveries from Crevier Project